Zydus Gives Up Attempt To Market Generic Astelin

Law360, New York (June 25, 2010, 12:27 PM EDT) -- Zydus Pharmaceuticals USA Inc. has admitted to infringing Meda Pharmaceuticals Inc.'s patent for azelastine hydrochloride nasal spray and consented not to attempt to market a generic version without Meda's consent.

Judge Mary L. Cooper of the U.S. District Court for the District of New Jersey signed off Thursday on findings of fact and a consent judgment and order, which said the suit was resolved and that each side would bear its own fees and costs.

According to the order, Zydus admitted that its filing of an...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.